Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia

MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

(2016) Roberta Biundo et al.   JOURNAL OF NEURAL TRANSMISSION

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

(2016) Brit Mollenhauer et al.   JOURNAL OF NEUROCHEMISTRY

Cerebrospinal fluid biomarkers for Alzheimerʼs disease

(2015) Henrik Zetterberg   CURRENT OPINION IN PSYCHIATRY

Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

(2015) Zheng-Yu Wang et al.   INTERNATIONAL PSYCHOGERIATRICS

CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease

(2015) Mark Terrelonge et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Lewy body dementias

(2015) Zuzana Walker et al.   LANCET

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

(2015) Changqin Liu et al.   PARKINSONISM & RELATED DISORDERS

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients

(2015) Malin Wennström et al.   Alzheimers Research & Therapy

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

(2014) Flora H. Duits et al.   Alzheimers & Dementia

Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias

(2014) David R. Howlett et al.   BRAIN PATHOLOGY

Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies

(2014) Stephen N. Gomperts   Current Neurology and Neuroscience Reports

Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis

(2014) H.-F. Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

(2014) Hana Přikrylová Vranová et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

CSF biomarkers and clinical progression of Parkinson disease

(2014) S. Hall et al.   NEUROLOGY

Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease

(2014) Nagaendran Kandiah et al.   PARKINSONISM & RELATED DISORDERS

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

(2014) Oskar Hansson et al.   Alzheimers Research & Therapy

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

(2014) Lucilla Parnetti et al.   Frontiers in Aging Neuroscience

Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan

(2013) Carol Sheei-Meei Wang et al.   INTERNATIONAL PSYCHOGERIATRICS

Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment

(2012) Erik Portelius et al.   CURRENT PHARMACEUTICAL DESIGN

Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies

(2012) Hans Brunnström et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Multivariate classification of patients with Alzheimer’s and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study

(2012) Alexander V. Lebedev et al.   JOURNAL OF NEUROLOGY

Amyloid-β and τ biomarkers in Parkinson's disease–dementia

(2011) Mariateresa Buongiorno et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

(2011) N. S. M. Schoonenboom et al.   NEUROLOGY

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Synergistic Interactions between A , Tau, and  -Synuclein: Acceleration of Neuropathology and Cognitive Decline

(2010) L. K. Clinton et al.   JOURNAL OF NEUROSCIENCE

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies

(2009) Fredrik Boström et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS